S-1/A: Virpax Pharmaceuticals Eyes $4.4 Million in Best Efforts Offering to Bolster Working Capital

Virpax Pharmaceuticals is launching a best efforts offering of common stock and warrants, aiming to raise approximately $4.4 million for working capital and general corporate purposes.

Summary

• Virpax Pharmaceuticals is undertaking a best efforts offering consisting of common stock, Series A-1 and A-2 warrants, and pre-funded warrants.
• The company aims to raise approximately $4.4 million before expenses, assuming the sale of all offered securities at an assumed price of $2.49 per share and accompanying warrants.
• Net proceeds will be used for working capital, general corporate purposes, and potentially to settle a $2.5 million obligation due July 1, 2024.
• The offering includes up to 2,008,032 shares of common stock, warrants to purchase additional shares, and pre-funded warrants as an alternative for investors exceeding beneficial ownership limits.
• A.G.P./Alliance Global Partners is acting as the exclusive placement agent for the offering.
• The offering is set to terminate on May 25, 2024, unless fully subscribed or terminated earlier by the company.
• The company's stock is listed on the Nasdaq Capital Market under the symbol VRPX.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the offering provides necessary capital, it also presents risks of dilution and market price decline. The company's financial situation and ongoing litigation add further uncertainty.

Positives

• The offering aims to strengthen the company's financial position by providing additional working capital.
• The inclusion of pre-funded warrants offers flexibility for investors with beneficial ownership limitations.
• The company has engaged A.G.P./Alliance Global Partners as the exclusive placement agent.

Negatives

• The offering is on a best efforts basis, meaning there is no guarantee that the company will raise the targeted $4.4 million.
• The company's stock price may be negatively impacted by the offering.
• New investors will experience immediate and substantial dilution in the net tangible book value of their shares.
• The company has a history of operating losses and may require additional financing in the future.
• The company is subject to certain covenants that restrict its ability to raise capital for a period of time after the closing of the offering.

Risks

• The company may not raise the targeted $4.4 million due to the best efforts nature of the offering.
• The company's stock price may decrease as a result of the offering.
• New investors will experience immediate and substantial dilution.
• The company has a history of operating losses and may require additional financing in the future.
• The company is subject to certain covenants that restrict its ability to raise capital for a period of time after the closing of the offering.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company is currently not in compliance with Nasdaq's minimum stockholders' equity requirement and may be delisted if it does not regain compliance.
• The company is subject to ongoing litigation that could negatively impact its cash position.

Future Outlook

The company intends to use the net proceeds from the sale of the Securities hereunder for working capital and general corporate purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Companys debt (other than payment of trade payables in the ordinary course of the Companys business and prior practices or as disclosed in the Registration Statement), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation, or (d) in violation of FCPA or OFAC regulations.

Industry Context

This offering reflects a common strategy for preclinical-stage pharmaceutical companies to raise capital for ongoing research and development activities. The use of best efforts offerings and warrants is a typical approach to attract investors in high-risk, high-reward ventures.

Comparison to Industry Standards

• Comparable companies in the preclinical stage often rely on similar financing methods, such as private placements, public offerings, and partnerships with larger pharmaceutical firms.
• The terms of the warrants, including exercise price and expiration date, are generally consistent with industry standards for similar offerings.
• The placement agent fee of 6.5% is within the typical range for best efforts offerings in the biotechnology sector.

Legal Proceedings

• The company entered into a Settlement Agreement and Mutual Release with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. to fully resolve all claims by the Plaintiffs against the Company related to the litigation captioned Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc. v. Anthony Mack and Virpax Pharmaceuticals, Inc., Case No. 2021-0210-PAF (the Action), subject to the entry by the United States Bankruptcy Court for the Southern District of Texas, which is handling the Sorrento bankruptcy filing (the Bankruptcy Court), of an order approving the Settlement Agreement (the Settlement Order).

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's employees and operations will benefit from the additional working capital.
• The company's creditors may be impacted by the use of proceeds to settle obligations.

Next Steps

• The company will file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto with the Commission within the time required by the Exchange Act.
• The company will apply to list all of the Shares and the Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and the Warrant Shares on such Trading Market.

Key Dates

Keywords

offering, warrants, common stock, pre-funded warrants, capital, Virpax Pharmaceuticals, placement agent, A.G.P.